Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants.

PatientApr 16, 2026 (epub)
Clinical ResearchNeurologyOpen access

Carla Dias-Barbosa, Hisaka Igarashi, Ashley Duenas et al.

✦ AI-curated · Sources linked

In 30 seconds

This qualitative study explored the experiences of 41 adults with migraine in Japan who participated in a phase III randomized controlled trial of erenumab. Participants reported significant improvements in migraine frequency, severity, and duration after 24 weeks of treatment, leading to enhanced daily functioning and quality of life. Satisfaction with erenumab averaged 6.8 on a 0-10 scale.

Key findings

  • Participants reported significant reductions in migraine frequency, severity, and duration after treatment.
  • Satisfaction with erenumab was high, with a mean score of 6.8 on a 0-10 scale.
  • Migraine symptoms such as pain, nausea, and fatigue were identified as the most bothersome prior to treatment.
  • Patients experienced improved daily functioning and quality of life due to treatment.

Why it matters

Understanding the lived experiences of migraine patients and their responses to new treatments like erenumab can inform clinical practice and enhance patient care strategies, ultimately improving quality of life for those affected by migraine.

Source

PubMed · PMID 41991782Free full text on PubMed Central

Published in Patient. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.